To determine the combined efficacy of piperlongumine and gemcitabine for treatment of KRAS mutant lung cancer.
Methods:
The cell growth inhibition of piperlongumine, gemcitabine, and piperlongumine plus gemcitabine was measured by Cell Counting Kit‑8 assay and the combination index was calculated. In addition, the combined effects of piperlongumine and gemcitabine on cell apoptosis, reactive oxygen species (ROS) contents, and microtubule-associated protein 1 light chain 3B (LC3B) expression were examined.
Results:
Piperlongumine increased ROS contents and LC3B-II expression. Following the combined treatment with piperlongumine and 10 mM N-acetyl-L-cysteine (NAC), intracellular ROS and cell viability returned to normal levels, and the expression of LC3B-II decreased to the predose level. Gemcitabine also induced cell apoptosis, increased ROS contents, and LC3B-II expression. The combination of piperlongumine with gemcitabine exhibited a synergetic anticancer activity with the combination index <1. The combined application of gemcitabine and piperlongumine yielded synergistic effects on cell apoptosis, but failed to synergistically increase ROS levels and LC3B-II expression.
Conclusion:
Combination therapy with piperlongumine and gemcitabine is a promising treatment option for KRAS mutant lung cancer.
BrayFFerlayJSoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018; 68: 394–424.
2.
SkoulidisFHeymachJV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer2019; 19: 495–509.
3.
LuangdilokSWanchaijiraboonPChantranuwatanaP, et al. Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer. Transl Lung Cancer Res2019; 8: 959–966.
4.
GuoJYWhiteE. Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors. Autophagy2013; 9: 1636–1638.
5.
SchaafMBKeulersTGVooijsMA, et al. LC3/GABARAP family proteins: autophagy-(un)related functions. FASEB J2016; 30: 3961–3978.
6.
LiuZRenZZhangJ, et al. Role of ROS and nutritional antioxidants in human diseases. Front Physiol2018; 9: 477.
7.
MoldogazievaNTLutsenkoSVTerentievAA. Reactive oxygen and nitrogen species-induced protein modifications: implication in carcinogenesis and anticancer therapy. Cancer Res2018; 78: 6040–6047.
8.
WengMSChangJHHungWY, et al. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. J Exp Clin Cancer Res2018; 37: 61.
9.
PiskaKGunia-KrzyżakAKoczurkiewiczP, et al. Piperlongumine (piplartine) as a lead compound for anticancer agents: synthesis and properties of analogues: a mini-review. Eur J Med Chem2018; 156: 13–20.
10.
SongXGaoTLeiQ, et al. Piperlongumine induces apoptosis in human melanoma cells via reactive oxygen species mediated mitochondria disruption. Nutr Cancer2018; 70: 502–511.
11.
YamaguchiYKasukabeTKumakuraS. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol2018; 52: 1011–1122.
12.
RajLIdeTGurkarAU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature2011; 475: 231–234.
13.
PrasadSTyagiAK. Historical spice as a future drug: therapeutic potential of piperlongumine. Curr Pharm Des2016; 22: 4151–4159.
14.
de Sousa CavalcanteLMonteiroG. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol2014; 741: 8–16.
15.
JuHQGochoTAguilarM, et al. Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation. Mol Cancer Ther2015; 14: 788–798.
16.
WangYChangJLiuX, et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging2016; 8: 2915–2926.
17.
CanonJRexKSaikiAY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature2019; 575: 217–223.
18.
NagasakaMLiYSukariA, et al. KRAS G12C Game of thrones, which direct KRAS inhibitor will claim the iron throne?Cancer Treat Rev2020; 84: 101974.
19.
MoysanEBastiatGBenoitJP. Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Mol Pharm2013; 10: 430–444.
20.
ZhouLQiLJiangL, et al. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol. AAPS J2014; 16: 246–257.
21.
PauwelsBKorstAELardonF, et al. Combined modality therapy of gemcitabine and radiation. Oncologist2005; 10: 34–51.
22.
MöhlerHPfirrmannRWFreiK. Redox-directed cancer therapeutics: taurolidine and piperlongumine as broadly effective antineoplastic agents (review). Int J Oncol2014; 45: 1329–1336.
23.
DA Silva MachadoFMunariFMScariotFJ, et al. Piperlongumine induces apoptosis in colorectal cancer HCT 116 cells independent of Bax, p21 and p53 status. Anticancer Res2018; 38: 6231–6236.
24.
RandhawaHKibbleKZengH, et al. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In Vitro2013; 27: 1626–1633.
25.
ThongsomSSugintaWLeeKJ, et al. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway. Apoptosis2017; 22: 1473–1484.
26.
AroraSBhardwajASinghS, et al. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated upregulation of CXCR4. J Biol Chem2013; 288: 21197–21207.
27.
WangHWangYGaoH, et al. Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways. Oncol Lett2018; 15: 1423–1428.
28.
XiongXXLiuJMQiuXY, et al. Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways. Acta Pharmacol Sin2015; 36: 362–374.
29.
WangYWangJWXiaoX, et al. Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis2013; 4: e824.
30.
ZhuJChenYJiY, et al. Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells. Biotechnol Appl Biochem2018; 65: 665–671.
